BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol 2015; 7(7): 954-967 [PMID: 25954478 DOI: 10.4254/wjh.v7.i7.954]
URL: https://www.wjgnet.com/1948-5182/full/v7/i7/954.htm
Number Citing Articles
1
Maria Guarino, Marco Picardi, Anna Vitiello, Novella Pugliese, Matilde Rea, Valentina Cossiga, Fabrizio Pane, Nicola Caporaso, Filomena Morisco. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for LymphomaAnnals of Hepatology 2017; 16(2): 198 doi: 10.5604/16652681.1231579
2
Marcela V. Maus, Michail S. Lionakis. Infections associated with the new ‘nibs and mabs’ and cellular therapiesCurrent Opinion in Infectious Diseases 2020; 33(4): 281 doi: 10.1097/QCO.0000000000000656
3
Xiaoyang Li, Yu Zheng, Hongming Zhu, Xiaojing Lin, Yunxiang Zhang, Yubing Zhao, Jiong Hu, Junmin Li. Risk of Onset of Hematological Malignancies in Patients Infected with the Hepatitis B Virus: Results from a Large-Scale Retrospective Cohort Study in ChinaActa Haematologica 2017; 137(4): 209 doi: 10.1159/000468973
4
Bilal Toka, Ahmet Tarik Eminler, Emel Gönüllü, Mukaddes Tozlu, Mustafa Ihsan Uslan, Erkan Parlak, Oğuz Karabay, Aydin Seref Koksal. Rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive therapyRheumatology International 2019; 39(12): 2077 doi: 10.1007/s00296-019-04437-y
5
Malowane H. Ngoato, Edina Amponsah-Dacosta, Ntombifuthi Blose, Selokela G. Selabe, Thembeni L. Msibi, Mojakgomo H. Motswaledi, Andrew M. Musyoki. Hepatitis B virus infection in patients presenting for immunosuppressive cancer therapy with and without underlying HIV infectionFrontiers in Virology 2023; 3 doi: 10.3389/fviro.2023.1160078
6
Charat Thongprayoon, Wisit Kaewput, Konika Sharma, Karn Wijarnpreecha, Napat Leeaphorn, Patompong Ungprasert, Ankit Sakhuja, Franco H Cabeza Rivera, Wisit Cheungpasitporn. Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysisWorld Journal of Hepatology 2018; 10(2): 337-346 doi: 10.4254/wjh.v10.i2.337
7
Apostolos Koffas, Upkar Gill, Patrick Kennedy. Evidence‐based Gastroenterology and Hepatology 4e2019; : 490 doi: 10.1002/9781119211419.ch33
8
G. I. Gridneva, B. S. Belov, E. S. Aronova. Chronic viral hepatitis B and rheumatic diseases: Modern view on problemMedical alphabet 2022; (29): 20 doi: 10.33667/2078-5631-2022-29-20-28
9
Marco Fiore, Sebastiano Leone, Alberto Enrico Maraolo, Emilio Berti, Giovanni Damiani. Liver Illness and Psoriatic PatientsBioMed Research International 2018; 2018: 1 doi: 10.1155/2018/3140983
10
Francis Mugeni Wanyama, Rudolf Tauber, Alfred Mokomba, Catherine Nyongesa, Véronique Blanchard. The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, KenyaInfectious Disease Reports 2022; 14(3): 433 doi: 10.3390/idr14030047
11
Mitchell L. Shiffman. Management of Acute Hepatitis B Virus InfectionCurrent Hepatology Reports 2020; 19(3): 276 doi: 10.1007/s11901-020-00536-8
12
Chih-An Shih, Wen-Chi Chen. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapyWorld Journal of Clinical Cases 2021; 9(21): 5769-5781 doi: 10.12998/wjcc.v9.i21.5769
13
Betül ERSÖZ ACAR. İmmünsüpresif ilaçlar ve HBV reaktivasyonuBolu Abant Izzet Baysal Universitesi Tip Fakultesi Abant Tip Dergisi 2022;  doi: 10.47493/abantmedj.1051982
14
Riha Vaidya, Joseph M. Unger, Rohit Loomba, Jessica P. Hwang, Rashmi Chugh, Monica A. Tincopa, Kathryn B. Arnold, Dawn L. Hershman, Scott D. Ramsey. Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency EvaluationCancer Research Communications 2023; 3(9): 1959 doi: 10.1158/2767-9764.CRC-23-0255
15
Funda PEPEDİL TANRİKULU, Didar YANARDAĞ AÇIK, Bilal AYGUN, Mehmet BANKİR, Mikail ÖZDEMİR. The compliance of our practice of hepatitis B virus screening with the current guidelines in patients undergoing chemotherapy for hematological malignanciesJournal of Surgery and Medicine 2021; 5(11): 1095 doi: 10.28982/josam.981625
16
Priyanka Vashisht, James O’dell. Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differencesExpert Opinion on Biological Therapy 2017; 17(8): 989 doi: 10.1080/14712598.2017.1340453
17
Gretchen L. Bentz, Angela J. Lowrey, Dustin C. Horne, Vy Nguyen, Austin R. Satterfield, Tabithia D. Ross, Abigail E. Harrod, Olga N. Uchakina, Robert J. McKallip, Luwen Zhang. Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latencyPLOS ONE 2019; 14(5): e0217578 doi: 10.1371/journal.pone.0217578
18
Romina Salpini, Arianna Battisti, Luna Colagrossi, Domenico Di Carlo, Lavinia Fabeni, Lorenzo Piermatteo, Carlotta Cerva, Miriam Lichtner, Claudio Mastroianni, Massimo Marignani, Sarah Maylin, Constance Delaugerre, Filomena Morisco, Nicola Coppola, Aldo Marrone, Mario Angelico, Loredana Sarmati, Massimo Andreoni, Carlo‐Federico Perno, Francesca Ceccherini‐Silberstein, Valentina Svicher. A snapshot of virological presentation and outcome of immunosuppression‐driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infectionJournal of Viral Hepatitis 2019; 26(7): 846 doi: 10.1111/jvh.13101
19
Ryo Yamauchi, Yasuaki Takeyama, Kazuhide Takata, Atsushi Fukunaga, Kunitoshi Sakurai, Takashi Tanaka, Hiromi Fukuda, Sho Fukuda, Hideo Kunimoto, Kaoru Umeda, Daisuke Morihara, Keiji Yokoyama, Makoto Irie, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin AcetateInternal Medicine 2020; 59(9): 1163 doi: 10.2169/internalmedicine.3805-19
20
Alessandro Federico, Giuseppina Brancaccio, Marcello Dallio, Patrizia Iodice, Alessio Fabozzi, Salvatore Del Prete, Fortunato Ciardiello, Carmela Loguercio, Giovanni Battista Gaeta. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?Digestive and Liver Disease 2017; 49(2): 197 doi: 10.1016/j.dld.2016.11.004
21
Ilaria Lenci, Martina Milana, Giuseppe Grassi, Tommaso M Manzia, Carlo Gazia, Giuseppe Tisone, Roberta Angelico, Leonardo Baiocchi. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?World Journal of Gastroenterology 2020; 26(18): 2166-2176 doi: 10.3748/wjg.v26.i18.2166
22
Weiwei Tang, Ziyi Chen, Wenling Zhang, Ye Cheng, Betty Zhang, Fan Wu, Qian Wang, Shouju Wang, Dawei Rong, F. P. Reiter, E. N. De Toni, Xuehao Wang. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspectsSignal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-0187-x
23
Ju-Tao Guo, Haitao Guo. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeuticsAntiviral Research 2015; 122: 91 doi: 10.1016/j.antiviral.2015.08.005
24
Yen Loo Lim, Gerome Bohelay, Sho Hanakawa, Philippe Musette, Baptiste Janela. Autoimmune Pemphigus: Latest Advances and Emerging TherapiesFrontiers in Molecular Biosciences 2022; 8 doi: 10.3389/fmolb.2021.808536
25
María Buti, María L. Manzano, Rosa M. Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L. Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M. Zozaya, Miguel A. Simón, Luis E. Morano, José L. Calleja, María Yébenes, Rafael Esteban, Vincent Wong. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin studyPLOS ONE 2017; 12(9): e0184550 doi: 10.1371/journal.pone.0184550
26
Narmeen Rana, Bushra Munir, Nazeer Hussain, Nazia Imtiaz, Asif Gondal, Fahed Parvaiz. Seroprevalence, Biochemical Investigation and Risk Factor Assessment for HBV & HCV Infection in Hospital Based Patients of Islamabad, PakistanJournal of Bioresource Management 2020; 7(2): 10 doi: 10.35691/JBM.0202.0127
27
Chunyan Yuan, Jing Peng, Renxiang Xia, Jian He, Tianji Qiu, Yunqing Yao. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral TherapyFrontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.865124
28
Gérôme Bohelay, Frédéric Caux, Philippe Musette. Clinical and biological activity of rituximab in the treatment of pemphigusImmunotherapy 2021; 13(1): 35 doi: 10.2217/imt-2020-0189
29
Deborah Rund. Prophylaxis for hepatitis B reactivation during and after chemotherapy: many questions, some answersLeukemia & Lymphoma 2016; 57(6): 1249 doi: 10.3109/10428194.2015.1131279
30
Z. Liu, L. Jiang, G. Liang, E. Song, W. Jiang, Y. Zheng, C. Gong. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta‐analysis of prophylaxis managementJournal of Viral Hepatitis 2017; 24(7): 561 doi: 10.1111/jvh.12672
31
Igor Snast, Lihi Atzmony, Marius Braun, Emmilia Hodak, Lev Pavlovsky. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literatureJournal of the American Academy of Dermatology 2017; 77(1): 88 doi: 10.1016/j.jaad.2017.01.037
32
Serdar DURAK, Arif Mansur COŞAR. Evaluation of the safety and antiviral efficacy of the tenofovir alafenamide fumarate molecule in immunosuppressed patientsJournal of Health Sciences and Medicine 2022; 5(6): 1688 doi: 10.32322/jhsm.1179106
33
Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen. Prevention and management of hepatitis B virus reactivation in cancer patientsHepatology International 2016; 10(3): 407 doi: 10.1007/s12072-015-9692-3
34
Stijn J De Keukeleire, Tijl Vermassen, Zahra M Nezhad, Tessa Kerre, Vibeke Kruse, Hans Van Vlierberghe, Karim Vermaelen, Sylvie Rottey. Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?Immunotherapy 2021; 13(5): 409 doi: 10.2217/imt-2020-0273
35
Brian McMahon, Joan Block, Timothy Block, Chari Cohen, Alison A. Evans, Anu Hosangadi, W. Thomas London, Morris Sherman. Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care: Table 1.Journal of the National Cancer Institute 2016; 108(4): djv359 doi: 10.1093/jnci/djv359
36
Faisal Inayat, Fei Song, Nouman Safdar Ali, Muhammad Haseeb Aslam, Aishatu Aloma, Hilal Hachem, Muhammad Wasif Saif. Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 casesJournal of Oncology Pharmacy Practice 2019; 25(6): 1500 doi: 10.1177/1078155218790337
37
Jiang Chen, Renan Jin, Jie Zhao, Jinghua Liu, Hanning Ying, Han Yan, Senjun Zhou, Yuelong Liang, Diyu Huang, Xiao Liang, Hong Yu, Hui Lin, Xiujun Cai. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinomaCancer Letters 2015; 367(1): 1 doi: 10.1016/j.canlet.2015.06.019
38
Nobuhiko Nakamura, Hisashi Tsurumi, Masahito Shimizu. The Liver in Systemic Diseases2016; : 293 doi: 10.1007/978-4-431-55790-6_14